Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03316300 · ClinicalTrials.gov registry record · Phase 3
A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A
A Phase 3 study of Macular Telangiectasia Type 2 (MacTel), sponsored by Neurotech Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT03316300 is a Phase 3 study of Macular Telangiectasia Type 2 (MacTel) that has completed, run by Neurotech Pharmaceuticals. The registered enrollment target is 120 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT03316300, a Phase 3 study of Macular Telangiectasia Type 2 (MacTel), has completed, sponsored by Neurotech Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of the NT-501 implants in participants with macular telangiectasia type 2.
Conditions Studied
Interventions
- PROCEDURE Sham Procedure
- COMBINATION_PRODUCT NT-501
Study Locations (20)
California
- Scripps Clinic Medical Group - La Jolla
- Jules Stein Eye Institute / David Geffen School of Medicine - Los Angeles
- Byers Eye Institute at Stanford University - Palo Alto
- Bay Area Retina Associates - Walnut Creek
Maryland
- National Institute of Health, NIH - Bethesda
- Cumberland Valley Retina Consultants - Hagerstown
Other
- Lariboisiere Hospital - Paris
- Moorfields Eye Hospital NHS Foundation Trust - London
Colorado
- Retina Consultants of Southern Colorado, P.C. - Colorado Springs
Louisiana
- Retina Associates of New Orleans - Metairie
Michigan
- Associated Retinal Consultants, P.C. - Royal Oak
Nevada
- Sierra Eye Associates - Reno
Ohio
- Retina Associates of Cleveland, Inc. - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2017-11-24 |
| Est. Completion | 2022-09-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03316300
The ClinicalTrials.gov registry entry for NCT03316300 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurotech Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Macular Telangiectasia Type 2 (MacTel) appearing as the primary indexed condition, and to 2 interventions - of which Sham Procedure is the first listed.
NCT03316300 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Maryland, Other.
Frequently Asked Questions
What is clinical trial NCT03316300 about?
NCT03316300 is a clinical study titled "A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A". This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of the NT-501 implants in participants with macular telangiectasia type 2.
What is the current status of trial NCT03316300?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2017-11-24. Estimated completion is 2022-09-23.
What conditions does trial NCT03316300 study?
This clinical trial studies the following conditions: Macular Telangiectasia Type 2 (MacTel).
What interventions are being tested in trial NCT03316300?
The interventions under investigation include: Sham Procedure (PROCEDURE), NT-501 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03316300?
This trial is sponsored by Neurotech Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03316300 being conducted?
This trial has 20 study locations across California, Colorado, Louisiana, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.